Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC889 in adults with relapsed/refractory mantle cell lymphoma
CTR20221615Phase 2Active
- Sponsor
- Fosun Kairos
- Start
- Oct 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of FKC889 in mantle cell lymphoma (MCL), sponsored by Fosun Kairos. Started Oct 2022; status: active.
02
Drugs
FKC889
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20221615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221615.